Dual-Directional Note Outperforms

in a Weak Market

Trade Summary:

In March 2024, we launched an 18-month capped dual-directional barrier note linked to the Health Care Select Sector SPDR® Fund (XLV) and the iShares® U.S. Real Estate ETF (IYR). The structure provided two potential paths to gains: up to +15.75% if the weaker ETF appreciated by 15.75% or more at maturity, or 150% participation in the inverse value of moderate declines, provided neither ETF fell more than 25%. This trade expressed a defensive yet opportunistic view on healthcare and real estate, targeting enhanced returns in both sideways and mildly negative markets.

A line chart showing the performance of a Dual Directional Up/down trading strategy over time from March 6, 2024, to June 6, 2025. The chart includes multiple lines: blue for NOTE, yellow for IYR, pink for XLV, and black for the initial level. It also displays green and red dashed lines for maximum return and barriers respectively. The x-axis represents dates, and the y-axis represents percentage change from -30% to +20%.

Why We Highlighted this note:

This trade demonstrates how dual-directional notes can outperform in stagnant or modestly declining markets. While a direct investment in XLV and IYR would have produced flat or negative returns, the structured note turned sector weakness into double-digit gains. It also underscores the value of active management—recognizing when a trade’s risk-reward balance shifts and exiting before maturity to capture the best outcome.

Conclusion:

More importantly, disciplined monitoring and proactive selling maximized results and minimized downside risk. By reallocating capital rather than stretching for negligible incremental gains, we reinforced a core principle: success lies not only in building effective structures, but in timing exits to protect and enhance returns.

Performance & Exit Rationale:

Over the holding period, XLV emerged as the weaker performer, declining ~10% without breaching the downside barrier. The note’s 1.5× downside participation transformed this modest drop into a ~15% positive payout.

We sold 32 days before maturity after the payout potential had effectively peaked—less than 0.4% upside remained to the $1,157.50 cap, while downside risk was uncapped. XLV was trading near its 52-week low, and further material declines were unlikely. Conversely, a rebound in XLV would have reduced the payout. By locking in gains early, we preserved nearly the full benefit while avoiding asymmetric risk and freeing capital for higher-conviction trades.